With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.